How Taxol/paclitaxel kills cancer cells
Taxol (generic name paclitaxel) is a microtubule-stabilizing drug that is approved by the Food and Drug Administration for the treatment of ovarian, breast, and lung cancer, as well as Kaposi's sarcoma. It is used off-label to treat gastroesophageal, endometrial, cervical, prostate, and head an...
Gespeichert in:
| Veröffentlicht in: | Molecular biology of the cell 2014-09, Vol.25 (18), p.2677-2681 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2681 |
|---|---|
| container_issue | 18 |
| container_start_page | 2677 |
| container_title | Molecular biology of the cell |
| container_volume | 25 |
| creator | Weaver, Beth A |
| description | Taxol (generic name paclitaxel) is a microtubule-stabilizing drug that is approved by the Food and Drug Administration for the treatment of ovarian, breast, and lung cancer, as well as Kaposi's sarcoma. It is used off-label to treat gastroesophageal, endometrial, cervical, prostate, and head and neck cancers, in addition to sarcoma, lymphoma, and leukemia. Paclitaxel has long been recognized to induce mitotic arrest, which leads to cell death in a subset of the arrested population. However, recent evidence demonstrates that intratumoral concentrations of paclitaxel are too low to cause mitotic arrest and result in multipolar divisions instead. It is hoped that this insight can now be used to develop a biomarker to identify the ∼50% of patients that will benefit from paclitaxel therapy. Here I discuss the history of paclitaxel and our recently evolved understanding of its mechanism of action. |
| doi_str_mv | 10.1091/mbc.E14-04-0916 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4161504</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1561972404</sourcerecordid><originalsourceid>FETCH-LOGICAL-c575t-54f22ba2e45f6439809c2e16076cf3532d1533d3837003f89a06061a1ed2183c3</originalsourceid><addsrcrecordid>eNpVUE1PwzAMjRCIjcGZG-oNLt3sfLW5IKFpMKRJXMY5ytIUCv0YTTfGvydjYwLpSbbl52f7EXKJMERQOKoWdjhBHkOAQnlE-qiYirlI5XHIQagYBeU9cub9GwByLpNT0qOCIkOFfXI9bT6judk05WhpbFl0ZuPK6L0oSx9ZU1vXRtaF4pyc5Kb07mIfB-T5fjIfT-PZ08Pj-G4WW5GILhY8p3RhqOMil5ypFJSlDiUk0uZMMJqhYCxjKUsAWJ4qAxIkGnQZxZRZNiC3O93lalG5zLq6a02pl21RmfZLN6bQ_zt18apfmrXmKFEADwI3e4G2-Vg53-mq8NsXTO2aldcoJKqE8h_qaEe1beN96_LDGgS9tVcHe7VDriEg2Bsmrv5ed-D_-sm-ATcSdL0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1561972404</pqid></control><display><type>article</type><title>How Taxol/paclitaxel kills cancer cells</title><source>MEDLINE</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Weaver, Beth A</creator><creatorcontrib>Weaver, Beth A</creatorcontrib><description>Taxol (generic name paclitaxel) is a microtubule-stabilizing drug that is approved by the Food and Drug Administration for the treatment of ovarian, breast, and lung cancer, as well as Kaposi's sarcoma. It is used off-label to treat gastroesophageal, endometrial, cervical, prostate, and head and neck cancers, in addition to sarcoma, lymphoma, and leukemia. Paclitaxel has long been recognized to induce mitotic arrest, which leads to cell death in a subset of the arrested population. However, recent evidence demonstrates that intratumoral concentrations of paclitaxel are too low to cause mitotic arrest and result in multipolar divisions instead. It is hoped that this insight can now be used to develop a biomarker to identify the ∼50% of patients that will benefit from paclitaxel therapy. Here I discuss the history of paclitaxel and our recently evolved understanding of its mechanism of action.</description><identifier>ISSN: 1059-1524</identifier><identifier>EISSN: 1939-4586</identifier><identifier>DOI: 10.1091/mbc.E14-04-0916</identifier><identifier>PMID: 25213191</identifier><language>eng</language><publisher>United States: The American Society for Cell Biology</publisher><subject>Animals ; Antineoplastic Agents, Phytogenic - pharmacology ; Antineoplastic Agents, Phytogenic - therapeutic use ; Cell Cycle Checkpoints - drug effects ; Humans ; MBoC on Cell Biology and Human Health ; Neoplasms - drug therapy ; Paclitaxel - pharmacology ; Paclitaxel - therapeutic use</subject><ispartof>Molecular biology of the cell, 2014-09, Vol.25 (18), p.2677-2681</ispartof><rights>2014 Weaver. This article is distributed by The American Society for Cell Biology under license from the author(s). Two months after publication it is available to the public under an Attribution–Noncommercial–Share Alike 3.0 Unported Creative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0).</rights><rights>2014 Weaver. This article is distributed by The American Society for Cell Biology under license from the author(s). Two months after publication it is available to the public under an Attribution–Noncommercial–Share Alike 3.0 Unported Creative Commons License ( ). 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c575t-54f22ba2e45f6439809c2e16076cf3532d1533d3837003f89a06061a1ed2183c3</citedby><cites>FETCH-LOGICAL-c575t-54f22ba2e45f6439809c2e16076cf3532d1533d3837003f89a06061a1ed2183c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161504/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161504/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25213191$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Weaver, Beth A</creatorcontrib><title>How Taxol/paclitaxel kills cancer cells</title><title>Molecular biology of the cell</title><addtitle>Mol Biol Cell</addtitle><description>Taxol (generic name paclitaxel) is a microtubule-stabilizing drug that is approved by the Food and Drug Administration for the treatment of ovarian, breast, and lung cancer, as well as Kaposi's sarcoma. It is used off-label to treat gastroesophageal, endometrial, cervical, prostate, and head and neck cancers, in addition to sarcoma, lymphoma, and leukemia. Paclitaxel has long been recognized to induce mitotic arrest, which leads to cell death in a subset of the arrested population. However, recent evidence demonstrates that intratumoral concentrations of paclitaxel are too low to cause mitotic arrest and result in multipolar divisions instead. It is hoped that this insight can now be used to develop a biomarker to identify the ∼50% of patients that will benefit from paclitaxel therapy. Here I discuss the history of paclitaxel and our recently evolved understanding of its mechanism of action.</description><subject>Animals</subject><subject>Antineoplastic Agents, Phytogenic - pharmacology</subject><subject>Antineoplastic Agents, Phytogenic - therapeutic use</subject><subject>Cell Cycle Checkpoints - drug effects</subject><subject>Humans</subject><subject>MBoC on Cell Biology and Human Health</subject><subject>Neoplasms - drug therapy</subject><subject>Paclitaxel - pharmacology</subject><subject>Paclitaxel - therapeutic use</subject><issn>1059-1524</issn><issn>1939-4586</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVUE1PwzAMjRCIjcGZG-oNLt3sfLW5IKFpMKRJXMY5ytIUCv0YTTfGvydjYwLpSbbl52f7EXKJMERQOKoWdjhBHkOAQnlE-qiYirlI5XHIQagYBeU9cub9GwByLpNT0qOCIkOFfXI9bT6judk05WhpbFl0ZuPK6L0oSx9ZU1vXRtaF4pyc5Kb07mIfB-T5fjIfT-PZ08Pj-G4WW5GILhY8p3RhqOMil5ypFJSlDiUk0uZMMJqhYCxjKUsAWJ4qAxIkGnQZxZRZNiC3O93lalG5zLq6a02pl21RmfZLN6bQ_zt18apfmrXmKFEADwI3e4G2-Vg53-mq8NsXTO2aldcoJKqE8h_qaEe1beN96_LDGgS9tVcHe7VDriEg2Bsmrv5ed-D_-sm-ATcSdL0</recordid><startdate>20140915</startdate><enddate>20140915</enddate><creator>Weaver, Beth A</creator><general>The American Society for Cell Biology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20140915</creationdate><title>How Taxol/paclitaxel kills cancer cells</title><author>Weaver, Beth A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c575t-54f22ba2e45f6439809c2e16076cf3532d1533d3837003f89a06061a1ed2183c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Animals</topic><topic>Antineoplastic Agents, Phytogenic - pharmacology</topic><topic>Antineoplastic Agents, Phytogenic - therapeutic use</topic><topic>Cell Cycle Checkpoints - drug effects</topic><topic>Humans</topic><topic>MBoC on Cell Biology and Human Health</topic><topic>Neoplasms - drug therapy</topic><topic>Paclitaxel - pharmacology</topic><topic>Paclitaxel - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Weaver, Beth A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Molecular biology of the cell</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Weaver, Beth A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>How Taxol/paclitaxel kills cancer cells</atitle><jtitle>Molecular biology of the cell</jtitle><addtitle>Mol Biol Cell</addtitle><date>2014-09-15</date><risdate>2014</risdate><volume>25</volume><issue>18</issue><spage>2677</spage><epage>2681</epage><pages>2677-2681</pages><issn>1059-1524</issn><eissn>1939-4586</eissn><abstract>Taxol (generic name paclitaxel) is a microtubule-stabilizing drug that is approved by the Food and Drug Administration for the treatment of ovarian, breast, and lung cancer, as well as Kaposi's sarcoma. It is used off-label to treat gastroesophageal, endometrial, cervical, prostate, and head and neck cancers, in addition to sarcoma, lymphoma, and leukemia. Paclitaxel has long been recognized to induce mitotic arrest, which leads to cell death in a subset of the arrested population. However, recent evidence demonstrates that intratumoral concentrations of paclitaxel are too low to cause mitotic arrest and result in multipolar divisions instead. It is hoped that this insight can now be used to develop a biomarker to identify the ∼50% of patients that will benefit from paclitaxel therapy. Here I discuss the history of paclitaxel and our recently evolved understanding of its mechanism of action.</abstract><cop>United States</cop><pub>The American Society for Cell Biology</pub><pmid>25213191</pmid><doi>10.1091/mbc.E14-04-0916</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1059-1524 |
| ispartof | Molecular biology of the cell, 2014-09, Vol.25 (18), p.2677-2681 |
| issn | 1059-1524 1939-4586 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4161504 |
| source | MEDLINE; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Animals Antineoplastic Agents, Phytogenic - pharmacology Antineoplastic Agents, Phytogenic - therapeutic use Cell Cycle Checkpoints - drug effects Humans MBoC on Cell Biology and Human Health Neoplasms - drug therapy Paclitaxel - pharmacology Paclitaxel - therapeutic use |
| title | How Taxol/paclitaxel kills cancer cells |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-20T23%3A58%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=How%20Taxol/paclitaxel%20kills%20cancer%20cells&rft.jtitle=Molecular%20biology%20of%20the%20cell&rft.au=Weaver,%20Beth%20A&rft.date=2014-09-15&rft.volume=25&rft.issue=18&rft.spage=2677&rft.epage=2681&rft.pages=2677-2681&rft.issn=1059-1524&rft.eissn=1939-4586&rft_id=info:doi/10.1091/mbc.E14-04-0916&rft_dat=%3Cproquest_pubme%3E1561972404%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1561972404&rft_id=info:pmid/25213191&rfr_iscdi=true |